导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.03% | 1215/4773 |
| 近一周 | 1.69% | 122/5491 |
| 近一月 | -4.17% | 2872/5408 |
| 近一季 | -10.96% | 4310/5202 |
| 近半年 | 1.89% | 955/4919 |
| 近一年 | 7.83% | 1411/4356 |
| 近两年 | 105.02% | 561/2950 |
| 近三年 | 56.57% | 459/2241 |
| 成立以来 | 44.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.73% 2882/4961 |
39.35% 818/5312 |
- - |
- - |
| 2025 | 46.51% 588/4813 |
-2.46% 2890/3635 |
3.33% 1048/4076 |
47.13% 487/4524 |
-1.20% 2867/4813 |
| 2024 | 8.32% 1569/3463 |
-5.81% 1953/2808 |
-5.83% 1806/3014 |
25.23% 311/3129 |
-2.48% 2106/3463 |
| 2023 | -16.37% 1681/2656 |
1.78% 1514/2280 |
-5.76% 1527/2385 |
-9.55% 1851/2515 |
-3.60% 735/2655 |
| 2022 | -25.18% 1295/2207 |
-18.27% 1315/1919 |
8.09% 393/2016 |
-16.49% 1461/2113 |
1.42% 1274/2208 |
| 2021 | 18.30% 212/1822 |
-11.69% 1140/1255 |
25.16% 95/1330 |
4.76% 321/1466 |
2.17% 669/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 诺安创业板指数增强(LOF)C VS. 长安沪深300非周期A(740101) |